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Abstract
Background: The role of chemotherapy in high-risk soft tissue sarcoma is controversial. Though many patients
undergo initial curative resection, distant metastasis is a frequent event, resulting in 5-year overall survival rates of
only 50-60%. Neo-adjuvant and adjuvant chemotherapy (CTX) has been applied to achieve pre-operative
cytoreduction, assess chemosensitivity, and to eliminate occult metastasis. Here we report on the results of our
non-randomized phase II study on neo-adjuvant treatment for high-risk STS.
Method: Patients with potentially curative high-risk STS (size ≥ 5 cm, deep/extracompartimental localization, tumor
grades II-III [FNCLCC]) were included. The protocol comprised 4 cycles of neo-adjuvant chemotherapy (EIA,
etoposide 125 mg/m
2 iv days 1 and 4, ifosfamide 1500 mg/m
2 iv days 1 - 4, doxorubicin 50 mg/m
2 day 1,
pegfilgrastim 6 mg sc day 5), definitive surgery with intra-operative radiotherapy, adjuvant radiotherapy and 4
adjuvant cycles of EIA.
Result: Between 06/2005 and 03/2010 a total of 50 subjects (male = 33, female = 17, median age 50.1 years) were
enrolled. Median follow-up was 30.5 months. The majority of primary tumors were located in the extremities or
trunk (92%), 6% originated in the abdomen/retroperitoneum. Response by RECIST criteria to neo-adjuvant CTX was
6% CR (n = 3), 24% PR (n = 12), 62% SD (n = 31) and 8% PD (n = 4). Local recurrence occurred in 3 subjects (6%).
Distant metastasis was observed in 12 patients (24%). Overall survival (OS) and disease-free survival (DFS) at 2 years
was 83% and 68%, respectively. Multivariate analysis failed to prove influence of resection status or grade of
histological necrosis on OS or DFS. Severe toxicities included neutropenic fever (4/50), cardiac toxicity (2/50), and
CNS toxicity (4/50) leading to CTX dose reductions in 4 subjects. No cases of secondary leukemias were observed
so far.
Conclusion: The current protocol is feasible for achieving local control rates, as well as OS and DFS comparable to
previously published data on neo-/adjuvant chemotherapy in this setting. However, the definitive role of
chemotherapy remains unclear in the absence of large, randomized trials. Therefore, the current regimen can only
be recommended within a clinical study, and a possibly increased risk of secondary leukemias has to be taken into
account.
Trial registration
ClinicalTrials.gov NCT01382030, EudraCT 2004-002501-72
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Soft tissue sarcomas (STS) comprise a large variety of
histologically distinct, rare malignant tumors. Overall,
they account for less than 1% of all adult malignancies
[1]. STS can occur in all anatomical sites, although
approximately 60% are found in the extremities with
predilection of the lower limb [2]. A mainstay of cura-
tive treatment is complete surgical resection with nega-
tive histological margins of the primary tumor and all
metastases, if possible. As treatment is complex, therapy
decisions should be made in an interdisciplinary team
involving oncologic surgeons, medical oncologists, sar-
coma pathologists, and radiation oncologists. Referral to
an experienced center is strongly recommended for this
rare entity. Although many patients undergo initial cura-
tive resection, distant metastasis is a frequent event in
up to 60% of all subjects, resulting in 5-year overall sur-
vival rates of approximately 50-60% for newly diagnosed
sarcoma patients [3-5].
For extremity tumors, improved local control rates have
been achieved by applying external beam radiotherapy
with doses of ≥ 50 Gy [6,7]. The timing of irradiation,
post- versus pre-operatively, does not seem to influence
local control rates. However, higher rates of wound com-
plications have been associated with pre-operative radio-
therapy, whereas post-operative irradiation might lead to
increased fibrosis and worse functional results [8]. As the
outcome for patients with distant metastasis is grim, stra-
tegies with neo-adjuvant and/or adjuvant chemotherapy
(CTX) have been explored to provide pre-operative cytor-
eduction, eliminate occult metastases, and assess chemo-
sensitivity. However, previous studies on CTX for high-
risk STS have yielded inconsistent results, and contempor-
ary approaches with surgery and radiotherapy alone have
shown excellent local control rates and overall survival [8].
So the definite role of CTX in this setting remains contro-
versial. Ifosfamide and doxorubicin are considered the sin-
g l em o s ta c t i v es u b s t a n c e si nS T S .H i s t o r i ct r i a l sr e p o r to n
response rates of 20-30% by conventional Response Eva-
luation Criteria in Solid Tumors (RECIST) for anthracy-
cline-based regimens [9,10]. However, more recent studies
suggest lower response rates of only 10-15% [11]. Many
centers will use combination regimens, especially in
younger patients, including epirubicin/ifosfamide, doxoru-
bicin/ifosfamide/mesna (AIM) and doxorubicin/ifosfa-
mide/mesna/dacarbazine (MAID). Unfortunately, the
promising overall response rates of ≥ 50% by RECIST in
phase II studies with aggressive CTX regimens in
advanced or metastatic disease could not be confirmed by
phase III results, and certainly do not reflect clinical rou-
tine [12]. Even further dose intensifications with autolo-
gous stem cell transplants have been explored, but cannot
be recommended outside a clinical trial [13].
In 2001 Issels et al. reported on a promising CTX
regimen combining etoposide, ifosfamide and adriamy-
cin (EIA) with regional hyperthermia [14]. We adopted
this regimen for our current protocol, choosing a neo-
and adjuvant CTX approach combined with definitive
surgery, intra-operative radiotherapy and post-operative
irradiation. The results of the corresponding phase III
trial by Issels et al. have been published recently:
hyperthermia added to EIA did significantly increase
response rate, local progression-free survival and dis-
ease-free survival, compared to CTX alone [15]. Here
we report on the final results of our study.
Methods
Patients
Patients with potentially curable, high-risk STS were
included in our phase II trial on “Neo-adjuvant Therapy
In Patients With High-Risk Soft Tissue Sarcoma”
(NeoWTS trial, ClinicalTrials.gov NCT01382030,
EudraCT 2004-002501-72). High-risk was defined as
tumor size ≥ 5 cm, Fédération Nationale des Centres de
Lutte Contre le Cancer (FNCLCC) grade II/III, deep or
extracompartimental localization, and patients with local
relapse or inadequate previous therapy. Inadequate pre-
vious therapy was defined as an initial, non-oncologic
surgical procedure on the primary tumor. Tumors with
sizes ≤ 5 cm after such a procedure were also eligible,
as per study protocol. Eligibility criteria furthermore
comprised classical soft tissue sarcoma histology accord-
ing to the WHO classification of soft tissue tumors (e.g.
liposarcoma, leiomyosarcoma, malignant fibrous histio-
cytoma, synovial sarcoma, etc.), age 18 - 65 years, nor-
mal liver-, renal-, cardiac- and bone marrow function, as
well as a Karnofsky index ≥ 80%. Ewing’s sarcoma,
osteosarcoma, chondrosarcoma, Kaposi’s sarcoma and
chordoma histology was not permitted. Angiosarcoma
were excluded, as distinct susceptibility to taxane-based
regimens has been shown for metastatic disease [16,17].
The study was carried out according to Good Clinical
Practice and the principles set in the Declaration of Hel-
sinki in 1964, as well as all subsequent revisions. Writ-
ten informed consent was obtained from all patients
before participation in the trial. The study protocol was
approved by the corresponding institutional ethics com-
mittee and authorities. Histologies were centrally
reviewed by a reference pathologist (GM) and classified
according to the FNCLCC system. The same pathologist
graded the operative specimen for tumor necrosis
according to Salzer-Kuntschik [18].
Imaging studies
Staging with MRI and/or CT scans of primary tumor
site, fluorine-18-fluorodeoxyglucose PET (FDG-18-PET)
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formed at study entry. Target lesions were re-assessed
after two cycles of EIA with MRI and/or CT scans and
FDG-18-PET. Tumor response was graded according to
RECIST criteria by a radiologist experienced in muscu-
loskeletal imaging at the local department of radiology.
Scans did not undergo external review. Follow-up exams
with MRI and/or CT scans were scheduled every two
cycles of CTX, pre-operatively, post-operatively and
after study completion every 3 months for the first 2
years. Dynamic PET studies were performed after intra-
venous injection of 300-370 MBq FDG for 60 min. The
analysis of the PET images was performed together by
two nuclear medicine physicians (ADS and LGS) using
the software package PMod (PMod Technologies Ltd.,
Adlisvil, Switzerland) [19].
Chemotherapy
Patients received neo-adjuvant and adjuvant CTX as
an inpatient regimen consisting of ifosfamide 1500
mg/m
2 iv days 1-4, etoposide 125 mg/m
2 iv days 1
and 4, and adriamycin 50 mg/m
2 iv day 1 (EIA regi-
men, 8 cycles total). Mesna was given with 300 mg/
m
2 0 h, 4 h and 8 h after start of ifosfamide infusion.
Pegfilgrastim 6 mg sc was administered on day 5 to
avoid cycle delay or dose reductions. Granisetron 2
mg po days 1-5 or an equivalent 5-HT3 antagonist
was used as antiemetic prophylaxis. Therapy was con-
tinued on day +22 and required platelets ≥ 75/nl and
leukocytes ≥ 2,0/nl. Chemotherapy was administered
through an implantable port-catheter system or cen-
tral venous line.
Adjuvant therapy
Definitive surgery was scheduled after 4 cycles of neo-
adjuvant CTX. The protocol design furthermore com-
prised intra-operative irradiation, adjuvant radiation and
adjuvant CTX (as previously described). If patients
showed tumor progression after 2 cycles of neo-adjuvant
CTX by conventional RECIST criteria, subjects were
referred to definitive surgery immediately.
Radiation therapy
Irradiation was applied as intra-operative therapy
(IORT) and as adjuvant external beam radiation, as
soon as possible after definitive surgery. The post-opera-
tive approach was chosen because of the lower risk of
wound complications. The recommended dose was cal-
culated for each patient, under consideration of the indi-
vidual situation and nearby structures. Median target
doses for trunk and extremity tumors were 15 Gy dur-
ing IORT and 45 Gy for post-operative irradiation.
Patients who did not undergo IORT received adjuvant
radiotherapy with a target dose ≥ 60 Gy. Lower doses
were applied in patients with abdominal tumors, due to
radiosensitive structures (e.g. intestines).
Toxicity analysis
Clinical toxicities occurring after CTX were collected by
review of laboratory values and patients’ charts including
hematological toxicity, nausea/vomiting, changes in liver
function tests, changes in renal function and CNS toxi-
city. Cardiac function was monitored by echocardio-
grams. Toxicities were graded according to Common
Terminology Criteria for Adverse Events v3.0 (CTCAE),
published March 31, 2003, by the National Cancer Insti-
tute (NCI) [20].
Study design and statistical analysis
A prospective, non-randomized, phase II study design
was chosen. Sample size was calculated to complete
study accrual within approximately 5 years, based on
the frequency of newly diagnosed high-risk sarcoma
patients presenting at our center. Disease-free survival
(DFS) and overall survival (OS) were estimated using
the method of Kaplan and Meier. DFS was defined as
the time interval from the date of definitive surgery to
radiologically proven local or distant failure, or patient’s
death due to sarcoma-related causes. OS was defined as
the time interval from the date of therapy induction to
patient’s death or last follow-up. Significance levels were
set at 0.05. A Cox regression model was applied for uni-
and multivariate analysis. Differences in survival were
assessed by log-rank test. A logistic regression was used
to distinguish treatment response. Calculations were
made using SPSS software (version 16). Data was ana-
lyzed as of January 17, 2011.
Results
From 06/2005 to 03/2010 a total number of n = 51 sub-
jects were included in the study. One patient was
excluded after the first cycle of neo-adjuvant EIA, as
reference pathology revised histology to angiosarcoma
which was not permitted by the study protocol. There-
fore the current analysis comprised 50 patients (male =
33, female = 17, median age 50.1 years [range 24-65]).
Characteristics and results are summarized in Tables 1
and 2. Median follow-up was 30.5 months. The majority
of tumors were located in the extremities or trunk
(92%). Only 6% originated in the abdomen/retroperito-
neum. Localizations in detail were: upper extremity (8%,
n = 4), lower extremity (62%, n = 31), trunk (22%, n =
11), abdomen/retroperitoneum (6%, n = 3) and head/
neck (2%, n = 1). Histological subtypes included liposar-
coma (including 6 patients with myxoid/round cell his-
tology; overall 24%, n = 12), synovial sarcoma (18%, n =
9), sarcoma not otherwise specified (NOS, 18%, n = 9),
malignant fibrous histiocytoma (MFH, 16%, n = 8),
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with tumor grades II (42%, n = 21) and III (58%, n =
29). Initial tumor size at diagnosis was 5-10 cm (60%, n
=3 0 )a n d≥ 10 cm (40%, n = 20). Overall, 21 patients
(42%) had undergone previous surgery (excluding
planned incisional biopsy to establish diagnosis) before
definitive resection in the study protocol. This resulted
in tumor sizes ≤ 5 cm in 22% of patients (n = 11) at
study enrollment.
Response by RECIST criteria to neo-adjuvant CTX
was complete response (CR, 6%, n = 3), partial remis-
sion (PR, 24%, n = 12), stable disease (SD, 62%, n = 31)
and progressive disease (PD, 8%, n = 4). A total of five
patients did not undergo definitive surgery while partici-
pating in the protocol: two non-extremity patients were
regarded inoperable due to technical reasons, one
patient was diagnosed concomitantly with rectal cancer,
one patient declined surgery for the extent of the proce-
dure, and one patient had extensive tumor progression
with distant metastasis. After neo-adjuvant CTX,
patients received surgery, radiotherapy and adjuvant
chemotherapy as per protocol (62%, n = 31); surgery
and radiotherapy (22%, n = 11); radiotherapy alone (8%,
n = 4) or surgery without any further adjuvant treat-
ment (4%, n = 2). One patient refused radiotherapy but
received adjuvant CTX after surgery. Furthermore, one
subject did not undergo definitive surgery but received a
total of 8 cycles EIA. Overall, 30% of patients (15/50)
did not receive the adjuvant treatment, as per protocol.
Surgical status after neo-adjuvant CTX was R0 (82%, n
= 37), R1 (13%, n = 6) and R2 (4%, n = 2). Tumor
necrosis in operative specimen was Salzer-Kuntschik
grade 1 (no vital tumor cells, 18%, n = 8), grade 2 (sin-
gle vital tumor cells, 9%, n = 4), grade 3 (vital tumor <
10%, 9%, n = 4), grade 4 (vital tumor 10-50%, 24%, n =
11), grade 5 (vital tumor >50%, 36%, n = 16) and grade
Table 1 Patients’ characteristics
Patients: n=
Male 33
Female 17
Median age 50.1 years (range 24 - 65)
Histologies:
Liposarcoma 12
Synovial Sarcoma 9
Sarcoma not otherwise specified (NOS) 9
Malignant fibrous histiocytoma (MFH) 8
Leiomyosarcoma 5
Others 7
Localization:
Upper extremity 4
Lower extremity 31
Trunk 11
Abdomen/Retroperitoneum 3
Head/Neck 1
Tumor grade (FNCLCC):
Grade II 21
Grade III 29
Tumor size at diagnosis:
5 - 10 cm 30
>10 cm 20
Total number of patients: 50
Table 2 Treatment results
Response by RECIST criteria to nCTX: n=
Complete response (CR) 3
Partial response (PR) 12
Stable disease (SD) 31
Progressive disease (PD) 4
Adjuvant treatment:
Surgery + RTX + aCTX 31
Surgery + RTX 11
Surgery without further adj. treatment 2
RTX 4
No definitive surgery 5
Tumor necrosis (Salzer-Kuntschik):
Grade 1 (no vital tumor) 8
Grade 2 (single vital tumor cells) 4
Grade 3 (vital tumor < 10%) 4
Grade 4 (vital tumor 10-50%) 11
Grade 5 (vital tumor >50%) 16
Grade 6 (completely vital tumor) 2
Radiotherapy
Intra-operative RTX 37
Median dose 15 Gy (10 - 15 Gy)
Adjuvant RTX 45
Median dose 45.0 Gy (20 - 66 Gy)
Therapy failure:
Distant metastases: 12
Pulmonary 9
Lymph nodes 3
Other 1
Local failure 3
Distant and local failure: 1
Toxicity assessment (≥ CTCAE 3)
Hematological tox.1 8
Neutropenic fever 4
Cardiac tox. (any grade) 2
Ifosfamide-induced encephalopathy 4
Nausea/Vomiting 7
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radiotherapy was feasible in 37 subjects with a median
dose of 15 Gy (range 10-15 Gy). Adjuvant irradiation
was administered in 45 patients with a median dose of
45.0 Gy (range 20-66 Gy).
Local recurrence after definitive surgery occurred in 3
subjects (6%). Of the 5 patients not undergoing defini-
tive surgery in the protocol, all had progressive disease
and 4 out of 5 died. Distant metastases were observed
in 12 patients (24%) with pulmonary and lymph node
metastases in 9 and 3 cases, respectively. One individual
presented with pulmonary and lymph node metastases
at the same time, one patient showed osseous and cere-
bral metastases, and one subject had concomitant local
and distant failure.
OS and DFS at 2 years were 83% and 68%, respectively
(Figures 1 and 2). Median OS and DFS were not yet
reached. Multivariate analysis failed to prove influence
of histological subtype, resection status or grade of his-
tological necrosis on OS or DFS.
Overall, the chemotherapy regimen was well tolerated.
Severe toxicities included neutropenic fever in 8%
(CTCAE grade 3, 4/50), cardiac toxicity in 4% (CTCAE
grade 2, 2/50), and ifosfamide-induced encephalopathy
in 8% (CTCAE grade 3, 4/50) of patients, leading to
CTX dose reductions in the subsequent cycles in 4 sub-
jects. Hematological toxicity (leukopenia, thrombocyto-
penia or anemia CTCAE grade ≥ 3) was observed in
36% (18/50). Nausea and vomiting (CTCAE grade ≥ 3)
occurred in 14% of patients (7/50). During the study,
there were no relevant cases of renal- or hepatic toxicity
reported. One subject had an allergic reaction (CTCAE
grade 3) to etoposide during the first treatment cycle.
Subsequent doses were received with anti-allergic pre-
medication, and were well tolerated. Furthermore, one
patient experienced Coombs negative hemolysis
(CTCAE grade 3) after receiving the 2nd adjuvant CTX
cycle. The 3 rd CTX cycle had to be postponed for 2
weeks. Hemolysis resolved spontaneously. No CTX-
related deaths or cases of secondary leukemia were
reported so far.
PET exams were performed in 34 patients with data
on dynamic PET available in 31 subjects. The data of
this subgroup analysis has already been published [21].
Combining 2 variables (mean SUV and influx) of the
baseline, as well as follow-up study after completion of
2 cycles of neo-adjuvant CTX, allowed patient categori-
zation into responders (defined as ≤ 10% viable tumor
cells in tumor specimen after neo-adjuvant CTX) or
non-responders (defined as ≥ 10% viable tumor cells in
tumor specimen after neo-adjuvant CTX), with an accu-
racy of 83%. A linear correlation was found between
mean SUV of the first study and overall survival (r = -
0.5501, p < 0.05).
Discussion
The role of CTX in potentially curative, high-risk STS
remains controversial. Known risk factors in STS
include patient age, tumor size and depth, histological
subtype, tumor grade, vascular invasion, necrosis and
growth pattern [22,23]. Neo-adjuvant regimens have
Figure 1 Overall survival. Overall survival (in months) was
calculated from start of therapy to patient’s death or last follow-up,
using the method of Kaplan and Meier.
Figure 2 Disease-free survival. Disease-free survival (in months)
was calculated from definitive surgery to radiologically proven local
or distant failure or patient’s death due to sarcoma-related causes,
using the method of Kaplan and Meier.
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eliminate occult metastases and assess chemo-sensitivity.
To our knowledge, there is only one prospective trial
published addressing the effect of neo-adjuvant CTX in
a randomized fashion [24]. The 5-year overall- and dis-
ease-free survival rates for the CTX arm (doxorubicin
and ifosfamide) were reported with 65% and 56%. There
was no statistically significant difference from the non-
CTX arm (64% and 52%, respectively). Although not
empowered to prove definitive benefit of one arm, Gort-
zak et al. concluded that after a follow-up of 7 years,
major survival benefits for the CTX arm seemed unli-
kely. In contrast, a retrospective analysis by Grobmyer
et al. using doxorubicin and ifosfamide containing neo-
adjuvant regimens, indicated a significant improvement
in the 3-year disease-specific survival (83% vs. 62%) in
patients with high-grade extremity STS >10 cm [25].
The adjuvant setting faces a similar uncertain situa-
tion. A meta-analysis including 1953 patients published
by Pervaiz et al. suggested a better overall survival for
subjects receiving adjuvant CTX [26]. Furthermore, a
recent multivariate analysis of the French sarcoma data-
base indicated a benefit of adjuvant CTX, especially in
FNCLCC grade III tumors [27]. In contrast, Le Cesne et
al. found no statistically significant difference in overall
survival for patients with completely resected tumors
analyzing the combined data of the two largest, rando-
mized EORTC trials [28]. Summarizing these results,
the role of CTX for high-risk STS remains uncertain, as
an improvement in overall survival could not be ulti-
mately proven so far.
Here we present the data of our non-randomized
phase II trial on neo-adjuvant EIA CTX, followed by
surgery, radiation therapy and adjuvant EIA CTX. Two-
year overall and disease-free survival rates of 83% and
68%, and local and distant failure rates of 3% and 24%
respectively, were achieved.
Kraybill et al. reported with a median follow-up of 7.7
years on a study similar to our currently presented pro-
tocol [29]. Neo- and adjuvant MAID CTX (mesna, dox-
orubicin, ifosfamide, and dacarbazine) was combined
with surgery and radiotherapy. Estimated 5-year rates
for disease-free, distant disease-free-, and overall survival
were reported with 56.1%, 64.1% and 71.2%, respectively.
At 2 years, overall and disease-free survival rates were
89.1% and 65.6%. Local and distant failure occurred in
22.2% and 28.1% of patients after 5 years. Interestingly,
the majority of patients relapsed within the first 2 years
(local failure in 15.6% and distant metastasis in 26.6%).
Overall, these results resemble our own experience.
In 2001, Issels et al. reported on a phase II study com-
bining EIA CTX with regional hyperthermia in high-risk
STS [14]. We adopted the CTX regimen for our current
protocol. The results of the corresponding phase III trial
were published in 2010 [15]. Hyperthermia significantly
increased the benefit of EIA CTX compared to EIA
alone; regarding response rate, as well as disease-free
and local progression-free survival. Overall survival was
improved in patients receiving complete induction EIA
(4 cycles) and regional hyperthermia therapy. In the
CTX arm, DFS and OS rates at 2 years for the extremity
subgroup were reported with 57% and 81%, respectively.
Treatment response to EIA alone was 1% CR, 12% PR,
58% SD and 21% PD, and was significantly better in the
hyperthermia arm (p = .002). We observed similar DFS
and OS rates, however our response data more closely
resembles the combination therapy arm. Local progres-
sion at 2 years and distant failure rate for EIA alone
were 30% and 26%, respectively. The higher rate of local
progression is most probably attributable to a high pro-
portion of non-extremity STS in the above mentioned
study. It can be hypothesized that the additional effect
of hyperthermia is accentuated in those patients where
local control is hard to achieve. The reported non-
hematological toxicity profile (e.g. nausea/vomiting, car-
diotoxicity, neurotoxicity) was similar to our experience.
H o w e v e r ,t h el e u k o p e n i ar a t e( C T C A Eg r a d e≥ 3) of
63.5% appears higher than in our data. Two factors
might have influenced the hematological (combined
anemia, leukopenia and thrombocytopenia, CTCAE
grade ≥ 3) toxicity rate of 36% in our study. As per
study protocol, patients were only recommended to
have blood draws once weekly in between treatment
cycles, and were allowed to have them with their local
general practitioner. Collecting the hematological toxi-
city data, we were not able to retrieve all results, so the
rate of grade 3 and 4 toxicities might be underestimated.
Furthermore, all of our patients received pegfilgrastim
24 h after each CTX cycle.
With a median follow-up time of 34 months, 5 cases
of secondary leukemia were reported, most probably
attributable to addition of etoposide in the current
regimen. Issels et al. therefore concluded that they will
abandon the EIA regimen in further studies. We did
not observe any cases of secondary leukemia so far.
However, since the activity of etoposide in STS is
questionable, and its additional leukemogenic potential,
we will also not pursue the EIA regimen in further
studies.
Previous studies found a statistically significant impact
of grade of necrosis after neo-adjuvant treatment, surgi-
cal status, and histological subtype on OS and/or DFS
[30-33]. We were unable to reproduce these results in
uni- and multivariate analysis. This might be attributable
to the fact that 30% (15/50) did not receive the adjuvant
treatment as per protocol, and also to small patient
numbers in subgroups, although OS and DFS seem
comparable to the previously outlined studies.
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ging question, and there has been an ongoing debate
about whether response by conventional RECIST criteria
reflects the specific biology of STS [34,35]. Strategies
with functional imaging (e.g. FDG-18-PET and dynamic
MRI scans) have been used to assess early tumor
response to neo-adjuvant treatment [36-38]. Our own,
already published data, supports this [21]. Combining
mean SUV and influx of the baseline, and follow-up
FDG-PET study after completion of 2 cycles of neo-
adjuvant CTX, allowed patient categorization into
responders (defined as ≤ 10% viable tumor cells in
tumor specimen after neo-adjuvant CTX) or non-
responders (defined as ≥ 10% viable tumor cells in
tumor specimen after neo-adjuvant CTX), with an accu-
racy of 83%. Further research will be needed to validate
these results and translate them into clinical practice.
It is most likely that due to the wide spectrum of his-
tological subtypes, systemic treatment for STS will
change in the upcoming years as more of the underlying
pathophysiological pathways are elucidated and treat-
ment is individualized. Combination regimens of classi-
cal CTX with new substances like pazopanib, a
angiogenesis inhibitor with promising activity in meta-
static disease [39], are currently tested in phase II
studies.
Conclusion
The current protocol is feasible with a manageable spec-
trum of side effects. No treatment-related deaths or cases
of secondary leukemia were observed so far. The reported
DFS and OS rates at 2 years (68% and 83%, respectively)
are in line with previously published studies, but the addi-
tional beneficial effect of regional hyperthermia combined
with EIA as shown by Issels et al. has to be taken into
account. Still it is most likely that not all patients benefit
from CTX, and the definitive role of CTX in STS remains
unclear in the absence of large, randomized trials. In our
opinion, CTX can be considered on an individual basis for
high-risk patients. However, possible advantages and dis-
advantages have to be discussed with the patient in detail.
Due to the questionable activity of etoposide and the
increased risk of secondary leukemias, we would not
recommend the currently presented EIA regimen outside
a clinical trial, and will not pursue it in further studies.
Further research is needed to assess treatment response
early on and spare non-responders from toxic side effects.
The identification of novel therapeutic targets and func-
tional imaging (e.g. with FDG-PET and dynamic MRI) will
help to achieve this goal.
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